Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Clinical trial NCT06449482 · TERMINATED
Trial details
- NCT number
- NCT06449482
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-05
- Primary completion
- 2025-03-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.